Additionally, SPP1 is highly expressed by male TAMs, which suggested that male NSCLC patients may benefit more from adjuvant immunotherapy targeting SPP1, however, this is dependent on verification in a larger cohort. Here, SPP1 is linked to non-small cell lung carcinoma.